Personalized dose selection platform for patients with solid tumors in the PRECISE CURATE.AI feasibility trial

Personalized dose selection platform for patients with solid tumors in the PRECISE CURATE.AI feasibility trial

Abstract In oncology, the conventional reliance on the maximum tolerated dose (MTD) strategy for chemotherapy may not optimize treatment outcomes for individual patients. CURATE.AI is an AI-derived platform that utilizes a patient’s own, small dataset to dynamically personalize only their own dose r...

Full description

Saved in:
Bibliographic Details
Main Authors: Agata Blasiak, Anh T. L. Truong, Nigel Foo, Lester W. J. Tan, Kirthika S. Kumar, Shi-Bei Tan, Chong Boon Teo, Benjamin K. J. Tan, Xavier Tadeo, Hon Lyn Tan, Cheng Ean Chee, Wei Peng Yong, Dean Ho, Raghav Sundar
Format: Article
Language:English
Published: Nature Portfolio 2025-02-01
Series:npj Precision Oncology
Online Access:https://doi.org/10.1038/s41698-025-00835-7
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1038/s41698-025-00835-7

Similar Items